HydroVax-001 is a vaccine candidate which consists of a hydrogen peroxide inactivated, whole virion (WNV-Kunjin strain) adjuvanted with aluminum hydroxide.
HydroVax-001 discovered and developed by scientists at the Oregon National Primate Research Center at Oregon Health & Science University (OHSU) in Portland.
HydroVax-001 is indicated to prevent West Nile virus.
The HydroVax-001 vaccine is currently administered intramuscularly in a two-dose series.
The OHSU research team, led by senior scientist Mark Slifka, Ph.D., created the investigational vaccine, HydroVax-001, with a novel, hydrogen peroxide-based process that renders the virus inactive while still maintaining key immune-system triggering surface structures.
The scientists were funded with a $7.2 million grant awarded in 2009 from NIAID, part of the National Institutes of Health.
The new vaccine is being tested in a Phase 1 clinical trial at Duke University in Durham, N.C., one of NIAID’s Vaccine and Treatment Evaluation Units (VTEUs).
January 28, 2019: The HydroVax-001 vaccine was found to be modestly immunogenic and well-tolerated at all dose levels.
Clinical Trial NCT02337868: Phase 1 Trial of Inactivated West Nile Virus Vaccine
- This trial will be a randomized, placebo-controlled, double-blind (within dosing group), dose escalation phase 1 trial, evaluating dosages of 1 mcg and 4 mcg of HydroVax-001 WNV vaccine given intramuscularly on Day 1 and Day 29 in up to 50 healthy adults > /=18 and < 50 years of age.
- The primary objective is to assess the safety, reactogenicity, and tolerability of the HydroVax-001 WNV vaccine administered intramuscularly in a two-dose series on Days 1 and 29 at a dose of 1 mcg or a dose of 4 mcg.